Rafael Molina

List of Publications by Year
in descending order

33 papers	1,840 citations	279798 23 h-index	414414 32 g-index
34 all docs	34 docs citations	34 times ranked	2465 citing authors

#	Article	IF	Citations
1	Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. Tumor Biology, 2005, 26, 281-293.	1.8	287
2	HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biology, 2011, 32, 1087-1095.	1.8	133
3	Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers. Clinical Chemistry, 2015, 61, 809-820.	3.2	120
4	ProGRP: a new biomarker for small cell lung cancer. Clinical Biochemistry, 2004, 37, 505-511.	1.9	118
5	Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor Biology, 2008, 29, 371-380.	1.8	107
6	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Research and Treatment, 1998, 51, 109-119.	2.5	104
7	Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with Histology. Tumor Biology, 2009, 30, 121-129.	1.8	94
8	Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program. Gastroenterology, 2014, 147, 628-636.e1.	1.3	94
9	Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomarkers, 2010, 6, 163-178.	1.7	75
10	Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. Clinical Chemistry, 2010, 56, 1148-1157.	3.2	70
11	Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Research, 2005, 25, 1773-8.	1.1	66
12	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biology, 2010, 31, 171-180.	1.8	61
13	S-100 Protein Serum Levels in Patients with Benign and Malignant Diseases: False-Positive Results Related to Liver and Renal Function. Tumor Biology, 2002, 23, 39-44.	1.8	56
14	Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate, 2000, 44, 271-274.	2.3	54
15	Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumor Biology, 2012, 33, 463-474.	1.8	52
16	Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases. Tumor Biology, 2004, 25, 56-61.	1.8	44
17	Prospective Evaluation of Squamous Cell Carcinoma<i></i>and Carcinoembryonic Antigen as Prognostic Factors in Patients with Cervical Cancer. Tumor Biology, 2003, 24, 156-164.	1.8	36
18	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1333-1340.	2.5	35

#	Article	IF	Citations
19	Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. , 2000, 42, 181-185.		31
20	Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. Clinica Chimica Acta, 2015, 438, 388-395.	1.1	30
21	Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumor Biology, 2011, 32, 13-22.	1.8	28
22	The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10Î¼g/L. Clinica Chimica Acta, 2014, 436, 303-307.	1.1	28
23	Circulating levels of HER-2/neu oncoprotein in breast cancer. Clinical Chemistry and Laboratory Medicine, 2012, 50, 5-21.	2.3	27
24	CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Research, 2005, 25, 1765-71.	1.1	26
25	Evaluation of two strategies for the interpretation of tumour markers in pleural effusions. Respiratory Research, 2017, 18, 103.	3.6	16
26	Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1945-1953.	2.3	15
27	Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer. Tumor Biology, 2018, 40, 101042831877220.	1.8	12
28	Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the AccessÂ® BR Monitor assay on the UniCelÂ® DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine, 2008, 46, 612-22.	2.3	10
29	A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. Tumor Biology, 2020, 42, 101042832095860.	1.8	3
30	Tumour markers with clinically controlled cutâ€offs for suspected cancer. European Journal of Clinical Investigation, 2021, 51, e13523.	3.4	3
31	Diagnostic Accuracy of CYFRA21-1 in the Differential Diagnosis of Pleural Effusions. Anticancer Research, 2019, 39, 5071-5076.	1.1	2
32	Very high levels of PSA in patients with cardiogenic shock: Report of four clinical cases. Clinical Biochemistry, 2020, 76, 42-44.	1.9	2
33	Comparative Assessment of Two Strategies for Interpreting Tumor Markers in Ascitic Effusions. In Vivo, 2020, 34, 715-722.	1.3	1